COMMUNIQUÉS West-GlobeNewswire

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
21/09/2026
- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised in full, together [...]
Acentra Health CEO Todd Stottlemyer Named to Virginia 500 Power List for Fifth Consecutive Year
21/09/2026
Recognition underscores the healthcare technology leader’s sustained commitment to Virginia’s business community and improved health outcomes nationwide MCLEAN, Va., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a [...]
BayCare Releases 2025 Physician and Provider Annual Report
21/09/2026
CLEARWATER, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- BayCare Health System today released Vital Impact, its 2025 Physician and Provider Annual Report, highlighting a year of clinical excellence, academic growth and [...]
Guardian Classic Welcomes Wounded Warrior Project as Official Sponsor Ahead of September 28 Charity Golf Tournament
21/09/2026
Two mission-driven nonprofit organizations team up to support active-duty, veterans, first responders and their families as the Guardian Classic enters its final days of registration and fundraising SAN DIEGO, Sept. 21 [...]
R3 Vascular Appoints Lisa Wipperman Heine to its Board of Directors
21/09/2026
Brings more than three decades of experience leading innovation across the medical technology industry MOUNTAIN VIEW, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to [...]
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
21/09/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder [...]
European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
21/09/2026
Johnson & Johnson introduces the first IL-23R targeted oral peptide that can deliver skin clearance and a favourable safety profile in a once-daily pill. 1,2 ICOTYDE™ (icotrokinra) offers an innovative new option [...]
Transactions under Novonesis’ share buyback program
21/09/2026
Please read the announcement in PDF Attachment 2026_18_Share_buyback
Siemens Healthineers and Novo Join Forces to Advance Care for People Living with MASLD and MASH
21/09/2026
Tarrytown, New York, USA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- People most at risk for MASLD/MASH remain largely unaware of the disease and its wider health risks Patients facing this metabolic condition benefit from [...]
Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
21/09/2026
NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its pivotal registrational Phase IIb study of opamtistomig [...]
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)
21/09/2026
Company announcement No. 49 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq [...]
ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
21/09/2026
ALK today announced the appointment of Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (CPPS), effective 1 October 2026. Tina succeeds Jacob Glenting, who headed CPPS before [...]
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
21/09/2026
CagriSema 1.0 mg/1.0 mg achieved superior weight loss of 12.4%* versus tirzepatide 5 mg of 9.1%* and non-inferior HbA 1c reduction at week 60 in adults with type 2 diabetes in REIMAGINE 5. CagriSema 1.0 mg/1.0 mg [...]
Underarm Pad Surface Area and Handle Angle: The Measurements Behind Crutch Comfort
21/09/2026
Drive Medical builds the MD by Drive Air-Crutch handle angle and grip size around load calculations run at the handgrip by Max Younger, who designed the crutch and now leads the line. The Airgonomic™ underarm cushion [...]
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
21/09/2026
BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
21/09/2026
The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that [...]
Seer Announces CFO Transition
21/09/2026
REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the [...]
Vironexis Announces Complete and Durable Responses in Relapsed/Refractory ALL Patients Treated with VNX-101
21/09/2026
In the ongoing SENTRY-CD19 trial, all three anti-AAV antibody-naïve patients with relapsed/refractory acute lymphoblastic leukemia (ALL) have achieved MRD-negative complete responses following a single administration of [...]
Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
21/09/2026
VISTA met its FDA-endorsed primary endpoint, demonstrating statistically significant low luminance visual acuity (LLVA) responder rates at Month 12 compared to the untreated control group A statistically significant [...]

Pages